Gilead to buy PepStar’s inflammation drug program in $1.28 billion deal

Gilead to buy PepStar's inflammation drug program in $1.28 billion deal

Gilead Agrees to Acquire PepStar’s Oral IL-23R Program for $1.275B

Lead candidate HCXT-2001 is in Phase 1. Closing is expected in the fourth quarter of 2026, subject to customary conditions.

Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche

Gilead agrees to acquire an oral IL-23R inhibitor from PepStar, while Zymeworks licenses its DLL3-targeting T cell engager ZW209 to Roche.

Gilead strikes $1.3B upfront China deal for oral IL-23 drug

Gilead is going to Shanghai for its latest expansion in the hot inflammation market, dishing out $1.28 billion upfront to PepStar Therapeutics for a Phase 1 asset. The California biopharma is gaining hold of an ...

Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a privately held, clinical-stage biotechnology company. Key Highlights HCXT-2001 is an investigational, clinical-stage, oral, macrocyclic peptide inhibitor of IL-23R with an extended more...